Browse the evidence

High LDL-C and low HDL-C are more prevalent in women, while hypertriglyceridemia is more prevalent in men in the Iranian adult population.

Lipid profiles differ by gender. Women in this population showed higher rates of low HDL and high cholesterol, while men showed higher rates of high triglycerides. Regular lipid screening is important for both genders, with attention to these specific patterns.

Caffeine ingestion (6 mg/kg) does not enhance power output during repeated short-term high-intensity exercise and may negatively affect performance in later bouts.

If you rely on caffeine for short, maximal sprints (like Wingate tests or repeated HIIT intervals), it likely won't help and might actually reduce your peak power in later sets. The traditional belief that caffeine boosts all high-intensity performance is not supported by this data. Save the caffeine for endurance activities where its benefits are clearer.

High consumption of trans-unsaturated fatty acids is associated with a significantly increased risk of developing laparoscopically confirmed endometriosis.

Minimize intake of trans-unsaturated fats, which are primarily found in commercially fried foods, margarine, and crackers, as high consumption is linked to a significantly higher risk of endometriosis. This supports public health efforts to remove trans fats from the food supply.

A 12-week combined resistance and high-intensity interval training program significantly increases skeletal muscle gene expression of kynurenine aminotransferase (KAT) isoforms and transcriptional coactivators (PGC-1α, PPARα, PPARδ) in healthy older men, but does not significantly alter circulating plasma kynurenine metabolites.

For older men, a 12-week program combining resistance and high-intensity interval training effectively upregulates the genetic machinery in muscles associated with mood regulation pathways (kynurenine pathway). However, this molecular shift does not immediately result in measurable changes in blood metabolite levels. Consistency is key, as the benefit lies in the local muscle adaptation rather than immediate systemic metabolic shifts.

Targeting a follow-up HbA1c level below 7.0% fails to maximize cardiovascular benefits and may increase the risk of heart failure and non-fatal stroke compared to maintaining levels above 7.0%.

If you have Type 2 Diabetes, aiming for an HbA1c below 7.0% may not provide the best cardiovascular protection and could increase your risk of heart failure. Current evidence suggests that maintaining levels slightly above 7.0% might offer better protection against major cardiovascular events. Discuss your specific cardiovascular risk profile with your doctor to determine the safest target.

The use of thiazolidinediones (TZDs) in intensive glucose control strategies significantly increases the risk of heart failure, whereas gliptins (DPP-4 inhibitors) show neutral effects.

If you are on intensive diabetes treatment, the specific medication matters for your heart health. Thiazolidinediones (TZDs) are associated with a higher risk of heart failure, while gliptins appear to have a neutral effect. Ensure your doctor considers your heart failure history when prescribing these medications.

Carrying the G alleles of ALPK1 polymorphisms rs2074388 or rs2074379 significantly increases the susceptibility to developing type 2 diabetes mellitus in Japanese individuals.

If you are of Japanese descent, knowing you carry specific ALPK1 variants (rs2074388 or rs2074379) means you have a higher genetic risk for type 2 diabetes. This does not mean you will definitely get it, but it suggests you should be vigilant about maintaining a healthy weight, managing blood sugar, and limiting inflammatory foods to counteract this predisposition.

Intensive lifestyle intervention (ILI) targeting weight loss in adults with type 2 diabetes does not improve cognitive function and may leave a legacy of relative cognitive deficits in subgroups with baseline obesity or cardiovascular disease history, an effect not mediated by changes in leptin or VEGF levels.

For individuals with Type 2 Diabetes, especially those with obesity or heart disease history, intensive lifestyle interventions aimed at significant weight loss may not improve cognitive function and might be associated with relative cognitive declines compared to less intensive support. This decline was not explained by changes in leptin or VEGF. Patients should focus on overall metabolic health and cardiovascular risk reduction, but should not expect cognitive enhancement from weight loss alone, and should monitor for any subjective cognitive changes.

Angiotensin-converting enzyme (ACE) inhibitors and Angiotensin II receptor blockers (ARBs) are the preferred antihypertensive treatments for diabetic patients due to renal protection and lack of adverse metabolic effects.

If you have diabetes and high blood pressure, ask your doctor about ACE inhibitors (ending in -pril) or ARBs (ending in -sartan). These are the preferred medications because they protect your kidneys and eyes, not just your heart. Avoid beta-blockers as a first choice if possible, as they can affect blood sugar. Aim for a blood pressure below 140/90 mmHg.

Massive weight loss induces metabolic adaptation (resting metabolic rate suppression beyond body composition changes) that is directly correlated with the magnitude of energy imbalance and the degree of circulating leptin reduction.

When you lose a large amount of weight, your body defends its previous weight by lowering your resting metabolic rate beyond what is explained by simply losing tissue. This 'metabolic adaptation' is driven by the size of your calorie deficit and the drop in leptin (a hormone from fat cells). To manage this, focus on maintaining energy balance rather than chronic severe deficits, as adaptation lessens when you stop losing weight.

Quitting smoking is associated with significant weight gain (5.17 lb over 4 years), while continued smoking is associated with less weight gain (-0.70 lb).

If you quit smoking, expect some weight gain (average 5.17 lb over 4 years). This is a common side effect of cessation. Focus on healthy dietary changes and increased physical activity to manage this. The health benefits of quitting smoking far outweigh the risks of weight gain.

Postmenopausal women using combined estrogen and progestin therapy experience a marked decrease in the risk of major coronary heart disease compared to non-users, with the addition of progestin not attenuating the cardioprotective effects of estrogen.

For postmenopausal women considering hormone therapy, current use of combined estrogen and progestin is associated with a significantly lower risk of major coronary heart disease compared to not using hormones. The addition of progestin does not appear to cancel out the heart-protective benefits of estrogen.

Current postmenopausal hormone therapy is associated with a significantly lower risk of all-cause mortality compared to never use, primarily driven by reduced coronary heart disease mortality.

For postmenopausal women currently using hormone therapy, there is a significant association with reduced all-cause mortality, largely due to lower heart disease death rates. This benefit is most pronounced in women with existing cardiovascular risk factors. However, the benefit diminishes with long-term use (10+ years) due to increased breast cancer mortality. Decisions should be individualized based on risk factors.

The mortality benefit of postmenopausal hormone therapy is attenuated with long-term use (10+ years) due to an increased risk of breast cancer mortality.

If you have been using hormone therapy for 10 or more years, the overall mortality benefit may be reduced due to an increased risk of breast cancer. This does not mean the therapy is harmful, but the net benefit is smaller than for short-term users. Discuss the balance of cardiovascular and breast cancer risks with your doctor.

Postmenopausal hormone therapy provides the greatest mortality benefit for women with existing cardiovascular risk factors.

If you are postmenopausal and have cardiovascular risk factors (such as high blood pressure, high cholesterol, smoking, or diabetes), hormone therapy may offer a significant reduction in your risk of death, primarily by reducing heart disease mortality. This benefit is much larger than for women with low cardiovascular risk.

Serum leptin levels correlate with subcutaneous (sc) adipose tissue volume, not visceral adipose tissue volume, in Asian Indian men.

Leptin levels reflect subcutaneous fat stores, not the dangerous visceral fat that drives insulin resistance. Do not use leptin as a proxy for visceral adiposity or metabolic risk in Asian Indian men. Focus on visceral fat reduction strategies instead.

Endurance training-like electrical stimulation selectively activates the AMPK-PGC-1α signaling pathway, which explains adaptations such as mitochondrial biogenesis and fast-to-slow muscle phenotype transformation without inducing muscle hypertrophy.

To improve mitochondrial health and endurance without gaining muscle size, focus on low-intensity, long-duration activities. This activates specific cellular pathways (AMPK) that optimize energy efficiency rather than building muscle mass.

Resistance training-like electrical stimulation selectively activates the PKB-TSC2-mTOR signaling cascade, leading to prolonged activation of translational regulators and increased muscle protein synthesis, resulting in hypertrophy.

To build muscle mass, focus on high-intensity resistance training. This activates specific cellular pathways (mTOR) that drive protein synthesis and muscle growth.

GLP-1 receptor agonists reduce hospitalizations for heart failure (HHF) by approximately 10-11%, although their effect on heart failure with reduced ejection fraction (HFrEF) is neutral or potentially harmful in small studies.

If you have Type 2 Diabetes and heart failure, GLP-1 RAs can help reduce the risk of being hospitalized for heart failure. However, if you have a specific type of heart failure where the heart muscle is weak (HFrEF), the data is less clear, and you should discuss the risks and benefits with your doctor.

Bariatric surgery is the most efficacious treatment for sustained weight loss and can induce long-term remission of type 2 diabetes in approximately 30% of patients, with Roux-en-Y gastric bypass being potentially more effective than sleeve gastrectomy for T2D remission.

For severe obesity, bariatric surgery is the most effective long-term treatment. It can lead to remission of type 2 diabetes in about 30% of patients and reduces the risk of heart disease and stroke. It is a serious medical intervention, not a cosmetic procedure.

A glucose disposal rate (GDR) below 5.6 mg/kgFFM+17.7 min during a 120 mU/m2·min hyperinsulinemic-euglycemic clamp identifies insulin resistance with 75% sensitivity and 71% specificity in white populations.

If you are undergoing metabolic testing, ask how your glucose disposal rate is normalized. For standard research clamps using high-dose insulin, a rate below 5.6 mg/kg fat-free mass per minute suggests insulin resistance. For routine clinical care, a HOMA-IR above 5.9, or between 2.8 and 5.9 combined with low HDL (<51 mg/dL), strongly predicts insulin resistance without needing a clamp.

Insulin resistance can be accurately predicted using routine clinical variables (HOMA-IR, HDL, fasting insulin) without performing a hyperinsulinemic-euglycemic clamp.

You do not need a specialized clamp test to screen for insulin resistance. Ask your doctor for a fasting insulin, glucose, and HDL test. If your HOMA-IR is above 5.9, or between 2.8 and 5.9 with low HDL (<51 mg/dL), you likely have insulin resistance.

Healthy aging is associated with an impaired ability to regulate energy intake, specifically through reduced hunger perception and increased post-meal satiation, leading to an inability to compensate for energy deficits and resulting in involuntary weight loss.

If you are older and experiencing unintentional weight loss, do not rely on hunger cues to tell you when to eat, as these signals are biologically impaired. You must eat on a schedule and prioritize energy-dense, palatable foods to maintain weight, as your body will not naturally compensate for missed meals.

Prior endurance or strength training history attenuates the acute phosphorylation of AMPK and Akt signaling pathways in response to divergent exercise stimuli, indicating that chronic adaptation blunts specific early signaling responses to non-habitual training modes.

If you are already well-trained in one type of exercise (e.g., running or weightlifting), switching to a different type (e.g., lifting or running) will not trigger the same intense initial signaling response as a beginner would experience. This does not mean the new exercise is ineffective; your body is simply more efficient. Focus on consistency and progressive overload rather than chasing acute 'burn' or signaling markers, as your adapted muscle handles stress differently.